Form D · Biotechnology
Cyrus Biotechnology, Inc.
Seattle, WA · CIK 0001641241
Offering snapshot reported May 8, 2026 · SEC filing
- Reported sold
- $1.48M Offering amount: $3M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 1, 2025 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$1,110,000 → $1,481,812
- Reported investors12 → 17
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 8, 2026 | Amendment | $1,481,812 | $371,812vs Jul 16, 2025 | 17 | SEC filing |
| Jul 16, 2025 | Initial | $1,110,000 | No comparison | 12 | SEC filing |
| Dec 31, 2024 | Initial | $3,183,997 | No comparison | 27 | SEC filing |
| Feb 29, 2024 | Initial | $2,694,470 | No comparison | 33 | SEC filing |
| Dec 2, 2021 | Amendment | $18,352,692 | $2,410,524vs Oct 6, 2021 | 34 | SEC filing |
| Oct 6, 2021 | Amendment | $15,942,168 | $6,840,411vs Jul 7, 2021 | 35 | SEC filing |
| Jul 7, 2021 | Initial | $9,101,757 | No comparison | Not reported | SEC filing |
| Sep 17, 2020 | Initial | $1,131,000 | No comparison | 19 | SEC filing |
| Jul 27, 2017 | Initial | $8,024,611 | No comparison | 18 | SEC filing |
| Feb 21, 2017 | Initial | $1,040,000 | No comparison | 13 | SEC filing |
| Nov 16, 2016 | Initial | $490,000 | No comparison | 14 | SEC filing |
| Apr 6, 2016 | Initial | $535,000 | No comparison | 14 | SEC filing |
| May 6, 2015 | Initial | $850,000 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-551903
Source: Form D, filed May 8, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eric Bell | Director |
| Mark Benjamin | Executive |
| Javier Castellanos | Executive |
| Nivon Lucas | Director, Executive, Promoter |
| Anthony Manning | Director |
| Lucas Nivon | Director, Executive |
| Ramakrishna Satyavolu | Director |
| Jason Smith | Director |
| Yifan Song | Director |
| Gus Tai | Director |
| Chad Waite | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3005 1 St Ave Suite 203
Seattle, WA, 98121
Seattle, WA, 98121